Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Intern Med. 2015 Jan 6;162(1):11-7. doi: 10.7326/M14-2255.

Effect of Ebola progression on transmission and control in Liberia.

Abstract

BACKGROUND:

The Ebola outbreak that is sweeping across West Africa is the largest, most volatile, and deadliest Ebola epidemic ever recorded. Liberia is the most profoundly affected country, with more than 3500 infections and 2000 deaths recorded in the past 3 months.

OBJECTIVE:

To evaluate the contribution of disease progression and case fatality on transmission and to examine the potential for targeted interventions to eliminate the disease.

DESIGN:

Stochastic transmission model that integrates epidemiologic and clinical data on incidence and case fatality, daily viral load among survivors and nonsurvivors evaluated on the basis of the 2000-2001 outbreak in Uganda, and primary data on contacts of patients with Ebola in Liberia.

SETTING:

Montserrado County, Liberia, July to September 2014.

MEASUREMENTS:

Ebola incidence and case-fatality records from 2014 Liberian Ministry of Health and Social Welfare.

RESULTS:

The average number of secondary infections generated throughout the entire infectious period of a single infected case, R, was estimated as 1.73 (95% CI, 1.66 to 1.83). There was substantial stratification between survivors (RSurvivors), for whom the estimate was 0.66 (CI, 0.10 to 1.69), and nonsurvivors (RNonsurvivors), for whom the estimate was 2.36 (CI, 1.72 to 2.80). The nonsurvivors had the highest risk for transmitting the virus later in the course of disease progression. Consequently, the isolation of 75% of infected individuals in critical condition within 4 days from symptom onset has a high chance of eliminating the disease.

LIMITATION:

Projections are based on the initial dynamics of the epidemic, which may change as the outbreak and interventions evolve.

CONCLUSION:

These results underscore the importance of isolating the most severely ill patients with Ebola within the first few days of their symptomatic phase.

PRIMARY FUNDING SOURCE:

National Institutes of Health.

Comment in

PMID:
25347321
PMCID:
PMC4402942
DOI:
10.7326/M14-2255
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center